
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is well positioned for sustained growth in the near term as evident from its strong Q1 2026 results, including earnings upside on Specialty & Care as well as evident MLR strength. Additionally, the company's focus on expanding its PBM and specialty pharmacy services, along with new client wins and strategic exits from less profitable business lines, further support its positive outlook. The company's commitment to diversity and accessibility also adds to its appeal for sustainable-minded investors.
Bears say
Cigna Group is facing execution risk in predicting and managing medical cost trends and network contracting, as well as potential impact from regulatory changes on rebate economics. Additionally, a potential economic downturn could negatively affect the company's earnings growth trajectory. However, the company's strong PBM selling season and secured business wins suggest continued competitiveness in the market, leading to estimates being raised and a price target of $337. Despite exiting certain business lines and focusing on core areas, the potential risk and investment in scaling the remaining lines may outweigh the potential benefit. Furthermore, the company's efforts to incorporate sustainability into its strategy through its Cigna Connects platform may help address global challenges and positively impact the company's reputation and operations.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares